| Budget Amount *help |
¥3,920,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥720,000)
Fiscal Year 2010: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2007: ¥800,000 (Direct Cost: ¥800,000)
|
|---|
| Research Abstract |
We identified that TCF8 at 10q11.2 is a candidate tumor-suppressor gene in acute-type adult-T cell leukemia/lymphoma (ATLL). The down-regulation of TCF8 expression by genetic and epigenetic abnormalities in ATLL was associated with resistance to TGF-beta1 treatment, which is one of well-known characteristics of ATL cells. The enforced expression of TCF8 partially restored the responsiveness of ATLL cells to TGF-beta1. Furthermore, TCF8 deficient mice frequently developed invasive CD4^+ T-cell lymphomas in thymus or in ascitic fluids. These findings suggest that TCF8 may become a new therapeutic target for ATLL.
|
